Categories: News

Glaukos Corporation to Release Third Quarter 2021 Financial Results after Market Close on November 4

Conference Call and Webcast Scheduled for 1:30 p.m. PDT

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2021 financial results after the market close on Thursday, November 4, 2021. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on November 4, 2021.

A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company’s website following completion of the call.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in 2012, its next-generation iStent inject® device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

Contacts

Chris Lewis

Sr. Director, Investor Relations & Corporate Strategy & Development

(949) 481-0510

clewis@glaukos.com

Staff

Recent Posts

MyndTec Inc. Completes Fourth Tranche of Non-Brokered Private Placement

Mississauga, Ontario--(Newsfile Corp. - March 19, 2024) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the…

3 hours ago

AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on…

5 hours ago

Vytalize Health Named to Forbes’ 2024 List of America’s Best Startup Employers

Prestigious business publication recognizes the value-based care enabler for its employer reputation, employee satisfaction, and…

5 hours ago

Masimo Named One of Fast Company’s Most Innovative Companies in North America

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products,…

8 hours ago

The Assistance Fund Becomes a Member of the National Health Council

ORLANDO, FL / ACCESSWIRE / March 19, 2024 / The Assistance Fund (TAF), an independent…

8 hours ago

Cell MedX Corp. Closes Private Placement Financing

Vancouver, British Columbia--(Newsfile Corp. - March 19, 2024) - Cell MedX Corp. (OTC Pink: CMXC)…

9 hours ago